Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

Cancer diagnosis and treatment are drastic events for patients and their families. Besides
psychological aspects of the disease, patients are often affected by severe side effects …

Oxaliplatin (OXA) is a commonly used platinum-based chemotherapy drug for colorectal
cancer. OXA-induced peripheral neurotoxcity (OIPN) is a comprehensive adverse reaction of …

Bortezomib, a first-generation proteasome inhibitor widely used in chemotherapy for
hematologic malignancy, has effective anti-cancer activity but often causes severe …

Oral cancer, as one of the most prevalent and invasive cancers that invade local tissue, can
cause metastasis, and have high mortality. In 2018, around 355,000 worldwide oral cancers …

Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a severe clinical problem and
potentially permanent side effect of cancer treatment. For the management of OIPN, accurate …

Peripheral neurologic complications are frequent adverse events during oncologic
treatments and often lead to dose reduction, administration delays with time elongation of …

Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating, and dose-
limiting side effect of many chemotherapy regimens yet has limited treatments due to …

Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling side effect caused by
neurotoxic chemotherapy. This randomized controlled trial aimed to evaluate the effect of …

Bortezomib is a pivotal drug for the management of multiple myeloma. However, bortezomib
is a neurotoxic anticancer drug responsible for chemotherapy-induced peripheral …